Increasing prescription of pre-exposure prophylaxis (PrEP) is imperative to ending the HIV
epidemic in the United States. The objective of this review was to identify health care …

More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …

Background There are few data available regarding the use of on-demand pre-exposure
prophylaxis (PrEP) for HIV prevention. We aimed to assess PrEP effectiveness, adherence …

We conducted a web-based survey to understand the impact of social distancing measures
on Brazilian MSM and transgender/non-binary lives. A total of 3486 respondents were …

The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

Background Daily pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but few
long-term data are available on effectiveness and adherence in real-world settings. Here …

Abstract Islatravir (MK-8591) is a highly potent type 1 human immunodeficiency virus (HIV-1)
nucleoside reverse transcriptase translocation inhibitor with a long intracellular half-life that …

The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region,
especially in the Central and Eastern subregions, are hindered by healthcare disparities …

Following recommendations by the World Health Organization in 2015, and key clinical
trials, countries in sub-Saharan Africa, the region with the highest burden of human …

Introduction The HIV epidemic continues to disproportionately impact Latin‐American
transgender women (TGW). We assessed factors associated with long‐term pre‐exposure …